Abstract
Schizophrenia, which is a chronic but episodic disorder of unknown etiology, shares immunological features with organ specific autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis and insulin-dependent diabetes mellitus. However, recent studies have raised the issue as to whether the reported immune disturbances in schizophrenia may be the result of a stress-induced dysregulation of CNS cytokine production, rather than a permanent immunological disorder, i.e., autoimmunity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39:784–794
Brown R, Li Z, Vriend CY, Nirula R, Janz L, Falk J, Nance DM, Dyck DG, Greenberg AH (1991) Suppression of splenic macrophage interleukin-1 secretion following intracerebroventricular injection of interleukin-1β: evidence of pituitary-adrenal and sympathetic control. Cell Immunol 132: 84 – 93
Bunney Jr WE, Hamburg DA (1963) Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry 9: 280 – 294
Carpenter Jr WT, Heinrichs DW, Wagman AMI (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145: 578 – 583
Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA (1987) The neuropsychiatric effects of treatment with interleukin-2 and lymphokine activated killer cells. Ann Intern Med 107: 293 – 300
Denicoff KD, Durkin TM, Lotze MT, Quinlan PE, Davis CL, Listwak SJ, Rosenberg SA, Rubinow DR (1989) The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 69: 402 – 410
Lapchek PA, Araujo DM, Quirion R, Beaudet A (1991) Immunoautoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain. Neurosci 44: 173 – 184
McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, Yao J, Peters JL (1995) Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 152: 1291 – 1297
Merrill JE (1990) Interleukin-2 effects in the central nervous system. Ann NY Acad Sci 594: 188 – 199
Merrill JE (1992) Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 14: 1 – 10
RamÃrez F, Fowell DJ, Puklavec M, Simmonds S, Mason D (1996) Glucocorticoids promote a Th2 cytokine response by CD4+ T cells in vitro. J Immunol 156: 2406 – 2412
Rook GAW, Hernandez-Panclo R, Lightman SL (1994) Hormones, peripherally acti-vated prohormones and regulation of the Thl/Th2 balance. Immunol Today 15: 301 – 303
Savino W, Dardenne M (1995) Immune-neuroendocrine interactions. Immunol Today 16: 318 – 321
Tandon R, Jibson MD, Taylor SF, DeQuardo JR (1995) Conceptual models of the relationship between positive and negative symptoms. In: Shriqui L, Nasrallah HA (eds) Contemporary issues in the treatment of schizophrenia. American Psychiatric Press, Washington DC, pp 109 – 124
Tarazona R, González-GarcÃa A, Zamzami N, Marchetti P, Frechin N, Gonzalo JA, Ruiz-Gayo M, van Rooijen N, MartÃnez-A. C, Kroemer G (1995) Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J Immunol 154: 861 – 870
van Kammen DP, Ågren H, Yao JK, O’Connor DT, Gurklis JA, Peters JL (1994) Nor-adrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am J Psychiatry 151: 379 – 384
van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Peters JL (1995) Behavioral vs. biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. Arch Gen Psychiatry 52: 673 – 678
van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Condray R, Peters JL (1996) Predicting duration of clinical stability following haloperidol withdrawal in schizophrenia. Neuropsychopharmacology 14:275–283
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag/Wien
About this paper
Cite this paper
van Kammen, D.P., McAllister, C.G., Kelley, M.E. (1997). Relationship between immune and behavioral measures in schizophrenia. In: Wieselmann, G. (eds) Current Update in Psychoimmunology. Key Topics in Brain Research. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6870-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6870-7_7
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83029-1
Online ISBN: 978-3-7091-6870-7
eBook Packages: Springer Book Archive